Quinolones

被引:18
作者
Alós, JI [1 ]
机构
[1] Hosp Mostoles, Microbiol Serv, Madrid 28935, Spain
来源
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA | 2003年 / 21卷 / 05期
关键词
quinolones; fluoroquinolones; antimicrobial agents; review;
D O I
10.1157/13046545
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Ouinolones act by inhibiting enzymes (topoisomerases), which are indispensable to DNA synthesis. Their bactericidal activity is concentration-dependent. Their spectrum has become broader, especially since the introduction of a fluorine atom at position 6 (fluoroquinolones). They are used as the treatment of choice or as alternative therapy in a wide variety of infections, both in the hospital and non-hospital setting. Depending on the compound, they are used in urinary tract infections, sexually transmitted diseases, chronic osteomyelitis, respiratory tract infections, and severe systemic infections, among others. The upsurge and extent of quinolone resistance has limited the use of these agents in some cases and in future may determine their use in others. There are strategies to minimize the spread of resistance. Quinolones are safe and well tolerated. The most frequent adverse effects are gastrointestinal and those affecting the central nervous system.
引用
收藏
页码:261 / 268
页数:8
相关论文
共 59 条
  • [1] Alos Cortes J I, 1997, Rev Clin Esp, V197, P167
  • [2] Comparative in vitro study of the activity of moxifloxacin and other antibiotics against 150 strains of penicillin non-susceptible Streptococcus pneumoniae and against 110 strains of ampicillin-resistant Haemophilus influenzae isolated in 1999-2000 in Spain -: J Antimicrob Chemother 2001; 48:145-148
    Alós, JI
    Oteo, J
    Aracil, B
    Gómez-Garcés, JL
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (01) : 145 - 148
  • [3] Alvarez F, 2001, Rev Esp Quimioter, V14, P87
  • [4] AMSDEN GW, 2000, PRINCIPLES PRACTICE, P253
  • [5] [Anonymous], 1998, MMWR Recomm Rep, V47, P1
  • [6] Single-dose ciprofloxacin versus 3 days of norfloxacin in uncomplicated urinary tract infections in women
    Auquer, F
    Cordón, F
    Gorina, E
    Caballero, JC
    Adalid, C
    Batlle, J
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2002, 8 (01) : 50 - 54
  • [7] Comparative tolerability of the newer fluoroquinolone antibacterials
    Ball, P
    Mandell, L
    Niki, Y
    Tillotson, G
    [J]. DRUG SAFETY, 1999, 21 (05) : 407 - 421
  • [8] BAQUERO F, 1990, EUR UROL, V17, P3
  • [9] Bartlett John G., 2000, Clinical Infectious Diseases, V31, P347, DOI 10.1086/313954
  • [10] Clinical role of protein binding of quinolones
    Bergogne-Bérézin, E
    [J]. CLINICAL PHARMACOKINETICS, 2002, 41 (10) : 741 - 750